# A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan

> **NCT07649252** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 82 (actual)

## Conditions studied

- Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07649252
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2022-11-20
- **Final completion:** 2022-11-20
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649252, "A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*